



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

30 January 2025
EMA/CHMP/552510/2024
Committee for Medicinal Products for Human Use (CHMP)

Summary of opinion¹ (initial authorisation)

Vimkunya

chikungunya vaccine (recombinant, adsorbed)

On 30 January 2025, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Vimkunya, a vaccine intended for the prevention of chikungunya disease in individuals aged 12 years and older. The applicant for this medicinal product is Bavarian Nordic A/S.

Vimkunya was reviewed under EMA's accelerated assessment programme.

Vimkunya will be available as a suspension for injection in a pre-filled syringe. It is an adjuvanted recombinant vaccine containing chikungunya virus (CHIKV) virus-like particles (VLPs) adsorbed on aluminium hydroxide. The VLPs consist of CHIKV capsid protein (C) and envelope proteins E1 and E2 derived from CHIKV Senegal strain 37997.

Vimkunya triggers the production of neutralising antibodies at 22 days and up to 183 days post-vaccination, which is expected to confer protection against chikungunya disease. The most common side effects are injection site pain, fatigue, headache, and myalgia.

The full indication is:

VIMKUNYA is indicated for active immunisation for the prevention of disease caused by chikungunya virus (CHIKV) in individuals 12 years and older.

The use of this vaccine should be in accordance with official recommendations.

Detailed recommendations for the use of this product will be described in the summary of product characteristics (SmPC), which will be published in the European public assessment report (EPAR) and made available in all official European Union languages after the marketing authorisation has been granted by the European Commission.

¹ Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 days from adoption of the opinion

